本项目针对组织工程化软骨在皮下植入环境中的表型不稳定问题，基于可抑制血管化的仿生细胞外基质构建策略，提出将一种新型的抗血管化小分子药物Axitinib引入到电纺明胶-聚己内酯（Gt-PCL）纳米纤维中，构建一个可抑制血管化的微环境，从而稳定软骨表型的研究设想。为此，项目将首先通过静电纺丝技术，制备出含量及释放速率稳定可控的载Axitinib的Gt-PCL纳米纤维材料，接着在细胞水平探讨材料的抗血管活性及毒副作用，最后探讨该载药纤维支架对骨髓基质干细胞（BMSCs）在大动物皮下环境中再生软骨的表型稳定作用与机制。本项目的顺利完成有望解决干细胞在皮下环境中容易骨化这一难题，推动组织工程软骨的临床应用转化，并为其它无血管组织如角膜、肌腱的再生提供参考。

Tissue engineered chondrocytes are known to be unstable in phenotype under the subcutaneous environment. In the current study, based on a strategy that mimics the native extracellular matrix, we propose an electrsopun gelatin-PCL (Gt-PCL) nanofibrous scaffold loaded with Axitinib (a novel anti-vascularization drug) to construct a microenvironment to inhibit vascularization, finally stabilizing the phenotype of regenerated chondrocytes. To this end, we will first prepare an Axitinib-loaded nanofibrous scaffold that has controlled release of drug via electrospinning. Then the anti-vascularization capability and side effect of the scaffold will be determined by cell study. At last, we will discuss the mechanism how the drug-loaded scaffold functions in the stabilization of regenerated chondrocytes with bone mesenchymal stem cells under subcutaneous condition using large animals. The proposal is expected to solve the problem that stem cells are feasibly committed osteogenic differentiation and also promote the clinical translation of tissue engineered chondrocytes, as well as provide a proof-of-principle for the regeneration of some other avascular tissues such as cornea and tendon.